{
  "first_published_at": "2011-04-04", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON111761", 
  "title": "Tigecycline (Tygacil▼): increased mortality in clinical trials – use only when other antibiotics are unsuitable", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 158, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Tigecycline (Tygacil&#9660;): increased mortality in clinical trials &#8211; use only when other antibiotics are unsuitable</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: April 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--An analysis of pooled results from clinical trials of tigecycline (Tygacil&#9660;) versus comparator drugs in a range of infections has shown numerically higher mortality rates in patients receiving tigecycline. Therefore, doctors are advised to use tigecycline only when other antibiotics are unsuitable.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>An analysis of pooled results from clinical trials of tigecycline (Tygacil&#9660;) versus comparator drugs in a range of infections has shown numerically higher mortality rates in patients receiving tigecycline. Therefore, doctors are advised to use tigecycline only when other antibiotics are unsuitable.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Tigecycline is a glycylcycline antibiotic approved for the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections.</p><p><font class=\"h3\">Results of pooled analysis</font></p><p>The licence holder for tigecycline completed a pooled analysis of results from all phase 3 and phase 4 trials in the approved indications (complicated skin and soft tissue infections and complicated intra-abdominal infections). Death occurred in 2.3% (52 of 2216) patients receiving tigecycline and 1.5% (33 of 2206) patients receiving comparator drugs.</p><p>A larger analysis adding results from trials of tigecycline use in unapproved indications (diabetic foot infections, nosocomial pneumonia, and treatment of resistant pathogens) also showed numerically higher overall mortality rates in patients treated with tigecycline versus those treated with active comparators.</p><p>The cause of these findings is unknown. The possibility that tigecycline has a poorer efficacy and/or safety profile than the comparator drugs cannot be excluded. Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome, including death.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><font class=\"h3\">Advice for healthcare professionals:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Tigecycline is approved only for treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections</li>\r\n\t\t\t\t<li>Tigecycline should only be used in situations where it is known or suspected that other drugs are unsuitable</li>\r\n\t\t\t\t<li>Numerically higher mortality rates have been reported in patients treated with tigecycline in clinical studies in approved and unapproved indications, compared with patients treated with other antibacterial agents</li>\r\n\t\t\t\t<li>Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome. Patients should be closely monitored for the development of superinfections. If medically indicated, they should be switched to alternative antibiotic treatment which has been shown to be efficacious in the treatment of the specific infection present</li>\r\n\t\t\t\t<li>Report suspected adverse reactions with tigecycline through the Yellow Card Scheme&mdash;see at <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">http://www.yellowcard.gov.uk</a>. When reporting, please provide as much information as possible, including information about medical history, concomitant medication, and dates of treatment and reaction onset</li>\r\n\t\t\t</ul></div><p><font class=\"h3\"><font color=\"#555555\" size=\"3\"><br></font>Further information:</font></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795\" target=\"_blank\">See letter for healthcare professionals sent March 2011</a></p><p>BNF section 5.1.3: <a href=\"http://bnf.org/bnf/bnf/current/129712.htm?q=tygacil&t=search&ss=text&p=1#_129712\" target=\"_blank\">Tetracyclines</a>&nbsp;(external link)</p><p><em>Article citation: Drug Safety Update April 2011; vol 4 issue 9: A1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Tigecycline is a glycylcycline antibiotic approved for the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections.</p><p><font class=\"h3\">Results of pooled analysis</font></p><p>The licence holder for tigecycline completed a pooled analysis of results from all phase 3 and phase 4 trials in the approved indications (complicated skin and soft tissue infections and complicated intra-abdominal infections). Death occurred in 2.3% (52 of 2216) patients receiving tigecycline and 1.5% (33 of 2206) patients receiving comparator drugs.</p><p>A larger analysis adding results from trials of tigecycline use in unapproved indications (diabetic foot infections, nosocomial pneumonia, and treatment of resistant pathogens) also showed numerically higher overall mortality rates in patients treated with tigecycline versus those treated with active comparators.</p><p>The cause of these findings is unknown. The possibility that tigecycline has a poorer efficacy and/or safety profile than the comparator drugs cannot be excluded. Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome, including death.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><font class=\"h3\">Advice for healthcare professionals:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Tigecycline is approved only for treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections</li>\r\n\t\t\t\t<li>Tigecycline should only be used in situations where it is known or suspected that other drugs are unsuitable</li>\r\n\t\t\t\t<li>Numerically higher mortality rates have been reported in patients treated with tigecycline in clinical studies in approved and unapproved indications, compared with patients treated with other antibacterial agents</li>\r\n\t\t\t\t<li>Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome. Patients should be closely monitored for the development of superinfections. If medically indicated, they should be switched to alternative antibiotic treatment which has been shown to be efficacious in the treatment of the specific infection present</li>\r\n\t\t\t\t<li>Report suspected adverse reactions with tigecycline through the Yellow Card Scheme&#8212;see at <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">http://www.yellowcard.gov.uk</a>. When reporting, please provide as much information as possible, including information about medical history, concomitant medication, and dates of treatment and reaction onset</li>\r\n\t\t\t</ul></div><p><font class=\"h3\"><font color=\"#555555\" size=\"3\"><br></font>Further information:</font></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795\" target=\"_blank\">See letter for healthcare professionals sent March 2011</a></p><p>BNF section 5.1.3: <a href=\"http://bnf.org/bnf/bnf/current/129712.htm?q=tygacil&amp;t=search&amp;ss=text&amp;p=1#_129712\" target=\"_blank\">Tetracyclines</a>&#160;(external link)</p><p><em>Article citation: Drug Safety Update April 2011; vol 4 issue 9: A1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-04-01", 
  "date_last_modified": "2011-04-04", 
  "_assets": [], 
  "_item_id": 158, 
  "summary": "An analysis of pooled results from clinical trials of tigecycline (Tygacil▼) versus comparator drugs in a range of infections has shown numerically higher mortality rates in patients receiving tigecycline. Therefore, doctors are advised to use tigecycline only when other antibiotics are unsuitable.", 
  "body": "Article date: April 2011\n\nTigecycline is a glycylcycline antibiotic approved for the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections.\n\nResults of pooled analysis\n\nThe licence holder for tigecycline completed a pooled analysis of results from all phase 3 and phase 4 trials in the approved indications (complicated skin and soft tissue infections and complicated intra-abdominal infections). Death occurred in 2.3% (52 of 2216) patients receiving tigecycline and 1.5% (33 of 2206) patients receiving comparator drugs.\n\nA larger analysis adding results from trials of tigecycline use in unapproved indications (diabetic foot infections, nosocomial pneumonia, and treatment of resistant pathogens) also showed numerically higher overall mortality rates in patients treated with tigecycline versus those treated with active comparators.\n\nThe cause of these findings is unknown. The possibility that tigecycline has a poorer efficacy and/or safety profile than the comparator drugs cannot be excluded. Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome, including death.\n\nAdvice for healthcare professionals:  \n  \n  * Tigecycline is approved only for treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections  \n  * Tigecycline should only be used in situations where it is known or suspected that other drugs are unsuitable  \n  * Numerically higher mortality rates have been reported in patients treated with tigecycline in clinical studies in approved and unapproved indications, compared with patients treated with other antibacterial agents  \n  * Patients who develop superinfections, particularly nosocomial pneumonia, seem to be at particular risk of having a poor outcome. Patients should be closely monitored for the development of superinfections. If medically indicated, they should be switched to alternative antibiotic treatment which has been shown to be efficacious in the treatment of the specific infection present  \n  * Report suspected adverse reactions with tigecycline through the Yellow Card Scheme—see at <http://www.yellowcard.gov.uk>. When reporting, please provide as much information as possible, including information about medical history, concomitant medication, and dates of treatment and reaction onset  \n  \n  \nFurther information:\n\n[See letter for healthcare professionals sent March 2011](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795)\n\nBNF section 5.1.3: [Tetracyclines](http://bnf.org/bnf/bnf/current/129712.htm?q=tygacil&t=search&ss=text&p=1#_129712) (external link)\n\nArticle citation: Drug Safety Update April 2011; vol 4 issue 9: A1\n"
}